253 related articles for article (PubMed ID: 15688384)
1. Anginex synergizes with radiation therapy to inhibit tumor growth by radiosensitizing endothelial cells.
Dings RP; Williams BW; Song CW; Griffioen AW; Mayo KH; Griffin RJ
Int J Cancer; 2005 Jun; 115(2):312-9. PubMed ID: 15688384
[TBL] [Abstract][Full Text] [Related]
2. The designed angiostatic peptide anginex synergistically improves chemotherapy and antiangiogenesis therapy with angiostatin.
Dings RP; Yokoyama Y; Ramakrishnan S; Griffioen AW; Mayo KH
Cancer Res; 2003 Jan; 63(2):382-5. PubMed ID: 12543791
[TBL] [Abstract][Full Text] [Related]
3. Scheduling of radiation with angiogenesis inhibitors anginex and Avastin improves therapeutic outcome via vessel normalization.
Dings RP; Loren M; Heun H; McNiel E; Griffioen AW; Mayo KH; Griffin RJ
Clin Cancer Res; 2007 Jun; 13(11):3395-402. PubMed ID: 17545548
[TBL] [Abstract][Full Text] [Related]
4. Antiangiogenesis therapy using a novel angiogenesis inhibitor, anginex, following radiation causes tumor growth delay.
Amano M; Suzuki M; Andoh S; Monzen H; Terai K; Williams B; Song CW; Mayo KH; Hasegawa T; Dings RP; Griffin RJ
Int J Clin Oncol; 2007 Feb; 12(1):42-7. PubMed ID: 17380440
[TBL] [Abstract][Full Text] [Related]
5. Combination of vascular endothelial growth factor receptor/platelet-derived growth factor receptor inhibition markedly improves radiation tumor therapy.
Timke C; Zieher H; Roth A; Hauser K; Lipson KE; Weber KJ; Debus J; Abdollahi A; Huber PE
Clin Cancer Res; 2008 Apr; 14(7):2210-9. PubMed ID: 18381963
[TBL] [Abstract][Full Text] [Related]
6. Anti-angiogenesis and anti-tumor activity of recombinant anginex.
Brandwijk RJ; Dings RP; van der Linden E; Mayo KH; Thijssen VL; Griffioen AW
Biochem Biophys Res Commun; 2006 Oct; 349(3):1073-8. PubMed ID: 16970922
[TBL] [Abstract][Full Text] [Related]
7. Recombinant adeno-associated virus-delivered anginex inhibits angiogenesis and growth of HUVECs by regulating the Akt, JNK and NF-κB signaling pathways.
Ma K; Wang C; Geng Q; Fan Y; Ning J; Yang H; Dong X; Dong D; Guo Y; Wei X; Li E; Wu Y
Oncol Rep; 2016 Jun; 35(6):3505-13. PubMed ID: 27035232
[TBL] [Abstract][Full Text] [Related]
8. Microbeam radiation therapy alters vascular architecture and tumor oxygenation and is enhanced by a galectin-1 targeted anti-angiogenic peptide.
Griffin RJ; Koonce NA; Dings RP; Siegel E; Moros EG; Bräuer-Krisch E; Corry PM
Radiat Res; 2012 Jun; 177(6):804-12. PubMed ID: 22607585
[TBL] [Abstract][Full Text] [Related]
9. Simultaneous inhibition of the receptor kinase activity of vascular endothelial, fibroblast, and platelet-derived growth factors suppresses tumor growth and enhances tumor radiation response.
Griffin RJ; Williams BW; Wild R; Cherrington JM; Park H; Song CW
Cancer Res; 2002 Mar; 62(6):1702-6. PubMed ID: 11912143
[TBL] [Abstract][Full Text] [Related]
10. Vascular endothelial growth factor tyrosine kinase inhibitor AZD2171 and fractionated radiotherapy in mouse models of lung cancer.
Cao C; Albert JM; Geng L; Ivy PS; Sandler A; Johnson DH; Lu B
Cancer Res; 2006 Dec; 66(23):11409-15. PubMed ID: 17145887
[TBL] [Abstract][Full Text] [Related]
11. Human glioblastoma and carcinoma xenograft tumors treated by combined radiation and imatinib (Gleevec).
Oertel S; Krempien R; Lindel K; Zabel A; Milker-Zabel S; Bischof M; Lipson KE; Peschke P; Debus J; Abdollahi A; Huber PE
Strahlenther Onkol; 2006 Jul; 182(7):400-7. PubMed ID: 16826359
[TBL] [Abstract][Full Text] [Related]
12. The designer anti-angiogenic peptide anginex targets tumor endothelial cells and inhibits tumor growth in animal models.
van der Schaft DW; Dings RP; de Lussanet QG; van Eijk LI; Nap AW; Beets-Tan RG; Bouma-Ter Steege JC; Wagstaff J; Mayo KH; Griffioen AW
FASEB J; 2002 Dec; 16(14):1991-3. PubMed ID: 12397082
[TBL] [Abstract][Full Text] [Related]
13. Anti-Vascular endothelial growth factor treatment augments tumor radiation response under normoxic or hypoxic conditions.
Lee CG; Heijn M; di Tomaso E; Griffon-Etienne G; Ancukiewicz M; Koike C; Park KR; Ferrara N; Jain RK; Suit HD; Boucher Y
Cancer Res; 2000 Oct; 60(19):5565-70. PubMed ID: 11034104
[TBL] [Abstract][Full Text] [Related]
14. Anti-tumor activity of the novel angiogenesis inhibitor anginex.
Dings RP; van der Schaft DW; Hargittai B; Haseman J; Griffioen AW; Mayo KH
Cancer Lett; 2003 May; 194(1):55-66. PubMed ID: 12706859
[TBL] [Abstract][Full Text] [Related]
15. Effects of cloned tumstatin-related and angiogenesis-inhibitory peptides on proliferation and apoptosis of endothelial cells.
Zhang GM; Zhang YM; Fu SB; Liu XH; Fu X; Yu Y; Zhang ZY
Chin Med J (Engl); 2008 Nov; 121(22):2324-30. PubMed ID: 19080341
[TBL] [Abstract][Full Text] [Related]
16. Protein kinase C-beta inhibitor enzastaurin (LY317615.HCI) enhances radiation control of murine breast cancer in an orthotopic model of bone metastasis.
Dudek AZ; Zwolak P; Jasinski P; Terai K; Gallus NJ; Ericson ME; Farassati F
Invest New Drugs; 2008 Feb; 26(1):13-24. PubMed ID: 17805485
[TBL] [Abstract][Full Text] [Related]
17. Cilengitide targeting of alpha(v)beta(3) integrin receptor synergizes with radioimmunotherapy to increase efficacy and apoptosis in breast cancer xenografts.
Burke PA; DeNardo SJ; Miers LA; Lamborn KR; Matzku S; DeNardo GL
Cancer Res; 2002 Aug; 62(15):4263-72. PubMed ID: 12154028
[TBL] [Abstract][Full Text] [Related]
18. Alpha-sulfoquinovosylmonoacylglycerol is a novel potent radiosensitizer targeting tumor angiogenesis.
Sakimoto I; Ohta K; Yamazaki T; Ohtani S; Sahara H; Sugawara F; Sakaguchi K; Miura M
Cancer Res; 2006 Feb; 66(4):2287-95. PubMed ID: 16489033
[TBL] [Abstract][Full Text] [Related]
19. Combination of anginex gene therapy and radiation decelerates the growth and pulmonary metastasis of human osteosarcoma xenografts.
Zhao K; Yang SY; Geng J; Gong X; Gong W; Shen L; Ning B
Cancer Med; 2018 Jun; 7(6):2518-2529. PubMed ID: 29659181
[TBL] [Abstract][Full Text] [Related]
20. The radiosensitizing effect of CpG ODN107 on human glioma cells is tightly related to its antiangiogenic activity via suppression of HIF-1α/VEGF pathway.
Liu D; Cao G; Cen Y; Liu T; Peng W; Sun J; Li X; Zhou H
Int Immunopharmacol; 2013 Oct; 17(2):237-44. PubMed ID: 23791618
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
